Tackling barriers to scale up human papillomavirus vaccination in China: progress and the way forward
Open Access
- 21 September 2023
- journal article
- editorial
- Published by Springer Nature in Infectious Diseases of Poverty
- Vol. 12 (1) , 1-6
Abstract
The human papillomavirus (HPV) vaccine is the first vaccine developed specifically targeting the prevention of cervical cancer. For more than 15 years, China has expedited a series of efforts on research and development of the domestically manufactured HPV vaccines, producing local population-based evidence, promoting free HPV vaccination from pilots, and launching action plans to tackle barriers in the scale-up of HPV vaccination. To further roll out the HPV vaccination program in China, several challenges should be addressed to support the steps forward. The availability of more locally manufactured HPV vaccines, pricing negotiation and local evidence supporting the efficacy of one-dose schedule would greatly alleviate the continued supply and financial constraints in China. Meanwhile, more attention should be paid to girls living in low-resource areas and males to ensure equal access to the HPV vaccination. Furthermore, linkage to secondary prevention and further real-world monitoring and evaluation are warranted to inform effective cervical cancer prevention strategies in the post-vaccine era. Graphical AbstractKeywords
Funding Information
- Bill and Melinda Gates Foundation (INV-031449, INV-018013)
- CAMS Innovation Fund for Medical Sciences (2021-I2M-1-004)
This publication has 11 references indexed in Scilit:
- Optimal allocation strategies for HPV vaccination introduction and expansion in China accommodated to different supply and dose schedule scenarios: a modelling studyeClinicalMedicine, 2022
- Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trialThe Lancet Infectious Diseases, 2022
- The eight-year long-term follow-up on the effectiveness of the quadrivalent human papillomavirus vaccine in Chinese women 20-45 years of ageHuman Vaccines & Immunotherapeutics, 2022
- Cancer incidence and mortality in China, 2016Journal of the National Cancer Center, 2022
- A nationwide post-marketing survey of knowledge, attitudes and recommendations towards human papillomavirus vaccines among healthcare providers in ChinaPreventive Medicine, 2021
- A nationwide post-marketing survey of knowledge, attitude and practice toward human papillomavirus vaccine in general population: Implications for vaccine roll-out in mainland ChinaVaccine, 2021
- [WHO's global strategy of cervical cancer elimination and the challenges and initiatives in China].2020
- Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical TrialJNCI: Journal of the National Cancer Institute, 2019
- Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-upVaccine, 2019
- The impact of HPV vaccination delays in China: Lessons from HBV control programsVaccine, 2013